zinc finger and SCAN domain containing 9Genealiases: PRD51 · ZNF193
Q-omics provides the consensus-scored ZSCAN9 profile across patient tissues and cancer cell-line models. ZSCAN9 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZSCAN9 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZSCAN9 RNA expression shows 20,663 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where ZSCAN9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN9 survival associations across molecular data types. ZSCAN9 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN9 RNA expression–survival associations across cancer types. High ZSCAN9 expression shows unfavorable associations in ACC, LIHC and KIRC, but favorable associations in BLCA, GBM and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZSCAN9 RNA expression.
This table summarizes ZSCAN9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZSCAN9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN9 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, LUAD, UCEC and COAD. The HNSC box plot shows higher ZSCAN9 RNA expression in tumor versus normal tissue (log2 FC = +0.487, t-test p < 0.001).
This table shows molecular features associated with ZSCAN9 in patient tissues and cancer cell lines. In patient samples, ZSCAN9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
